Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 25 recommendations for 18 medicines and 8 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
8.2.2. Targeted therapies
  1. Abemaciclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  2. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  3. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  4. Binimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  5. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  6. Cobimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  7. Crizotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 200 mg; 250 mg
    • Oral > Solid > capsule: 200 mg; 250 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive
  8. Dabrafenib General information
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
    Indications
    Other specified melanoma of skin
  9. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  10. Encorafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  11. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  12. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  13. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  14. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  16. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  17. Osimertinib General information
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
    Indications
    Other specified malignant neoplasms of bronchus or lung
  18. Palbociclib General information
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
    Indications
    Other specified malignant neoplasms of breast
  19. Pertuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
    Indications
    Carcinoma of breast, specialised type
  20. Ribociclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  21. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia
  22. Trametinib General information
    Section
    Targeted therapies
    • Oral > Solid: 0.5 mg; 2 mg
    Indications
    Other specified melanoma of skin
  23. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  24. Trastuzumab emtansine General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  25. Vemurafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  26. Zanubrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 80 mg
    Indications
    Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma